{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:44:53Z","timestamp":1777725893461,"version":"3.51.4"},"reference-count":100,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR\u201016\u2010RHUS\u20100007"],"award-info":[{"award-number":["ANR\u201016\u2010RHUS\u20100007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["13CVD03"],"award-info":[{"award-number":["13CVD03"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF20160936167"],"award-info":[{"award-number":["SPF20160936167"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Diabetic dyslipidaemia, characterized by quantitative, qualitative and kinetic changes in all major circulating lipids, contributes to the increased cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). A promising therapeutic avenue is the inhibition of the proprotein convertase subtilisin kexin 9 (PCSK9) with human monoclonal antibodies (mAbs) that potently reduce plasma low\u2010density lipoprotein cholesterol (LDL\u2010C) levels on top of statin treatment. The aim of this review is to evaluate the efficacy of PCSK9 inhibitors to lower the residual cardiovascular risk of T2DM patients and to discuss the safety of PCSK9 inhibition in these patients. PCSK9 inhibitors potently lower plasma LDL\u2010C levels in T2DM patients and reduce risk for the development of cardiovascular disease. Anti\u2010PCSK9 mAbs are generally not more or less effective in T2DM patients compared to a general high\u2010risk population. Nevertheless, due to their higher cardiovascular risk, the absolute risk reduction of major cardiovascular events is more significant in T2DM patients. This suggests that treatment of T2DM patients with anti\u2010PCSK9 mAbs could be attractive from a cost\u2010effectiveness perspective. Treatment with anti\u2010PCSK9 mAbs did not result in significant treatment\u2010emergent adverse effects. While genetic studies suggest a potential link between PCSK9 inhibition and glucose homeostasis, anti\u2010PCSK9 mAbs did not worsen glycaemic control in T2DM patients, but their safety should be verified after a longer\u2010term follow\u2010up.<\/jats:p>","DOI":"10.1111\/dom.13636","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T09:22:26Z","timestamp":1555665746000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of proprotein convertase subtilisin\/kexin 9 inhibitors in people with diabetes and dyslipidaemia"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-7751","authenticated-orcid":false,"given":"Wieneke","family":"Dijk","sequence":"first","affiliation":[{"name":"L'institut du thorax, INSERM, CNRS University of Nantes, CHU Nantes  Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"L'institut du thorax, INSERM, CNRS University of Nantes, CHU Nantes  Nantes France"},{"name":"CIC INSERM 1413, CHU Nantes, Department of Endocrinology L'institut du thorax  Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800256"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3525-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1263565"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.07.007"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2084"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030950"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-011-0219-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179564"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301621"},{"key":"e_1_2_8_21_1","unstructured":"EMA (European Medicine Agency). Praluent.https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/praluent. Published 2018. Accessed September 27 2018."},{"key":"e_1_2_8_22_1","unstructured":"FDA. Drugs@FDA.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Published 2018. Accessed September 27 2018."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.07.219"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025080"},{"key":"e_1_2_8_25_1","unstructured":"Alnylam. RNAi pipeline.http:\/\/www.alnylam.com\/alnylam-rnai-pipeline\/. Published 2018. Accessed September 27 2018."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.260"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0141"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.11.020"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.03.023"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2563"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12490"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2712"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12819"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508582200"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.305688"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P009860"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.10.028"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.03.022"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.12.009"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-10-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.07.098"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.03.013"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.126987"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140832"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000133684.77013.88"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000190668.94752.ab"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307995"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00684"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi128"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.250043"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0098"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2011.06.006"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140559"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.181586"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034710"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13450"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0439-8"},{"key":"e_1_2_8_59_1","first-page":"1","article-title":"Efficacy and safety of alirocumab in Japanese patients with diabetes mellitus: post\u2010hoc subanalysis of ODYSSEY Japan","author":"Teramoto T","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00003-6"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12788"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30313-3"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13384"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12909"},{"key":"e_1_2_8_65_1","first-page":"9","article-title":"Inclisiran lowers LDL\u2010C and PCSK9 irrespective of diabetes status: the ORION\u20101 randomized clinical trial","volume":"42","author":"Leiter LA","year":"2018","journal-title":"Diabetes Care"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.07.017"},{"key":"e_1_2_8_67_1","article-title":"PCSK9 inhibitor therapy: a systematic review and meta\u2010analysis of metabolic and cardiovascular outcomes in patients with diabetes","author":"Monami M","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13257"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13114"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.01.004"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23018"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025253"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R071233"},{"key":"e_1_2_8_75_1","first-page":"e9","article-title":"Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER trial","volume":"275","author":"O'Donoghue ML","year":"2018","journal-title":"Circulation"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy122"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20180040"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.5.1313"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117794"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14568"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.1884"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1206"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3374-x"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61183-1"},{"issue":"6","key":"e_1_2_8_85_1","first-page":"1077","article-title":"Statins and risk of incident diabetes: a collaborative meta\u2010analysis of randomised statin trials","volume":"29","author":"Sattar N","year":"2010","journal-title":"Rev Port Cardiol"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30396-5"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300102200"},{"key":"e_1_2_8_89_1","doi-asserted-by":"crossref","unstructured":"Da DaltL RuscicaM BonacinaF et al.PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low\u2010density lipoprotein receptor.2018;(July):1\u201313doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehy357.","DOI":"10.1093\/eurheartj\/ehy357"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.10.138"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.12.018"},{"key":"e_1_2_8_92_1","article-title":"What the diabetes data in FOURIER trial fail to show","author":"Bruggen FH","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw292"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.0747"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13235"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13817"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1541-4"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.07.008"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"29","key":"e_1_2_8_101_1","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser U","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13636","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:10:38Z","timestamp":1761876638000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":100,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/dom.13636"],"URL":"https:\/\/doi.org\/10.1111\/dom.13636","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13636\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13636\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}